BRPI1008441A2 - anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira. - Google Patents

anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.

Info

Publication number: BRPI1008441A2
Authority: BR; Brazil
Prior art keywords: antibody; humanized; composition; treating; subject
Prior art date: 2009-02-16

Application number

BRPI1008441A

Other languages

English (en)

Inventor

David G Williams

Original Assignee

Biolex Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-16

Filing date

2010-02-16

Publication date

2016-10-11

2010-02-16 Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc

2016-10-11 Publication of BRPI1008441A2 publication Critical patent/BRPI1008441A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Plant Pathology (AREA)
Transplantation (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI1008441A 2009-02-16 2010-02-16 anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira. BRPI1008441A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15277809P	2009-02-16	2009-02-16
US15349909P	2009-02-18	2009-02-18
PCT/US2010/000449 WO2010093480A2 (en)	2009-02-16	2010-02-16	Humanized anti-cd20 antibodies and methods of use

Publications (1)

Publication Number	Publication Date
BRPI1008441A2 true BRPI1008441A2 (pt)	2016-10-11

Family

ID=42562242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008441A BRPI1008441A2 (pt)	2009-02-16	2010-02-16	anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.

Country Status (12)

Country	Link
US (1)	US20100303808A1 (pt)
EP (1)	EP2396416A4 (pt)
JP (1)	JP2012517806A (pt)
KR (1)	KR20110128876A (pt)
CN (1)	CN102439163A (pt)
AU (1)	AU2010214082A1 (pt)
BR (1)	BRPI1008441A2 (pt)
CA (1)	CA2752286A1 (pt)
IL (1)	IL214627A0 (pt)
MX (1)	MX2011008611A (pt)
WO (1)	WO2010093480A2 (pt)
ZA (1)	ZA201106697B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7601689B2 (en) *	2007-04-12	2009-10-13	Naidu Lp	Angiogenin complexes (ANGex) and uses thereof
EP2690955A4 (en)	2011-03-30	2014-10-15	Univ Arizona	AURISTATINE TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOCHINOLINE DERIVATIVES AND PRODRUGS THEREOF
EP2729498A1 (en) *	2011-07-06	2014-05-14	MorphoSys AG	Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
AR087749A1 (es)	2011-09-01	2014-04-16	Eisai R&D Man Co Ltd	Anticuerpos anti-xcr1 humano
CN107384932B (zh) *	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
WO2018102795A2 (en)	2016-12-02	2018-06-07	University Of Southern California	Synthetic immune receptors and methods of use thereof
CA3046489A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
EP4021485A1 (en)	2019-08-28	2022-07-06	King's College London	B cell targeted parallel car (pcar) therapeutic agents
CN114555117A (zh) *	2019-10-12	2022-05-27	百奥泰生物制药股份有限公司	抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7321026B2 (en) *	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
CA2476166C (en) *	2002-02-14	2011-11-15	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
ES2347241T3 (es) *	2002-12-16	2010-10-27	Genentech, Inc.	Variantes de inmunoglobulina y sus utilizaciones.
CN1748143A (zh) *	2002-12-16	2006-03-15	健泰科生物技术公司	表达人cd20和/或cd16的转基因小鼠
WO2005000901A2 (en) *	2003-05-09	2005-01-06	Duke University	Cd20-specific antibodies and methods of employing same
ZA200706336B (en) *	2005-02-07	2009-01-28	Genentech Inc	CD20 antibody variants and uses thereof
CN101203607B (zh) *	2005-03-31	2012-09-05	生物医药股份有限公司	抗cd20单克隆抗体
US9382327B2 (en) *	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
CN100455598C (zh) *	2006-11-29	2009-01-28	中国抗体制药有限公司	功能人源化抗人cd20抗体及其应用

2010
- 2010-02-16 BR BRPI1008441A patent/BRPI1008441A2/pt not_active IP Right Cessation
- 2010-02-16 MX MX2011008611A patent/MX2011008611A/es not_active Application Discontinuation
- 2010-02-16 CN CN2010800164497A patent/CN102439163A/zh active Pending
- 2010-02-16 KR KR1020117021712A patent/KR20110128876A/ko not_active Withdrawn
- 2010-02-16 AU AU2010214082A patent/AU2010214082A1/en not_active Abandoned
- 2010-02-16 CA CA2752286A patent/CA2752286A1/en not_active Abandoned
- 2010-02-16 JP JP2011550135A patent/JP2012517806A/ja active Pending
- 2010-02-16 EP EP10741539A patent/EP2396416A4/en not_active Withdrawn
- 2010-02-16 WO PCT/US2010/000449 patent/WO2010093480A2/en not_active Ceased
- 2010-03-09 US US12/720,483 patent/US20100303808A1/en not_active Abandoned
2011
- 2011-08-11 IL IL214627A patent/IL214627A0/en unknown
- 2011-09-13 ZA ZA2011/06697A patent/ZA201106697B/en unknown

Also Published As

Publication number	Publication date
AU2010214082A1 (en)	2011-10-13
JP2012517806A (ja)	2012-08-09
IL214627A0 (en)	2011-09-27
CN102439163A (zh)	2012-05-02
US20100303808A1 (en)	2010-12-02
EP2396416A4 (en)	2013-02-27
MX2011008611A (es)	2011-10-21
ZA201106697B (en)	2014-01-29
KR20110128876A (ko)	2011-11-30
EP2396416A1 (en)	2011-12-21
WO2010093480A2 (en)	2010-08-19
CA2752286A1 (en)	2010-08-19

Similar Documents

Publication	Publication Date	Title
BRPI1008441A2 (pt)	2016-10-11	anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
BRPI1011324A2 (pt)	2016-03-15	sistema, método e cliente para participação em grupo
BR112014027166A2 (pt)	2017-06-27	anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
BR112014002621A2 (pt)	2017-12-12	anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112014003598A2 (pt)	2017-12-12	molécula de ligação de antígeno biespecífica, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir a molécula de ligação de antígeno biespecífica, composição farmacêutica, uso e método para tratar uma doença em um indivíduo
CL2014000449A1 (es)	2015-01-16	Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos.
BR112013030520A2 (pt)	2017-03-21	método, sistema, e, composição.
EP2660706A4 (en)	2015-01-21	METHOD AND SYSTEM FOR MANAGING AND CONTROLLING DOCUMENT PRINTING AND DOCUMENT SOURCE SCREENING
BR112014011137A2 (pt)	2018-06-12	polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
BRPI0910573A2 (pt)	2015-09-29	sistema para processar um pagamento de seguro de propriedade, e, método e sistema para prever pagamento de seguro de propriedade
BRPI0823030A2 (pt)	2015-07-28	Sistema de elevador, e, método para fazer um sistema de elevador.
BR112013031907A2 (pt)	2016-12-13	sistema, método e programa de computador para prever geomatria de poço
BRPI0816094A2 (pt)	2015-03-03	Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
BR112013015930A2 (pt)	2017-03-21	método para analisar pelo menos um fragmento emergindo de um poço, e conjunto para analisar pelo menos um fragmento emergindo de um poço.
IL206108A (en)	2013-07-31	Antibody @ Bi-value @ Bi-specific L @ method for its preparation, compounds containing it @ and cell @ surrogate
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI1014253A2 (pt)	2016-04-12	polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
BR112013018884A2 (pt)	2017-03-21	método para o tratamento de biomassa com um sistema de torrefação, e, sistema de torrefação para o tratamento de biomassa.
BRPI1012023A2 (pt)	2016-05-10	método implementado por computador, e métodos para operar um sistema de reservatório e para avaliar um esquema de injeção padrão ou um esquema de injeção periférica.
BR112013015893A2 (pt)	2018-06-05	método, sistema, e, meio legível por máquina não transitório.
BR112013007397A2 (pt)	2016-07-12	sistema para a autenticação, método para a autenticação, e método para permitir a autenticação,

Legal Events

Date	Code	Title	Description
2017-01-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2017-05-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2017-06-06	B25B	Requested transfer of rights rejected	Owner name: BIOLEX THERAPEUTICS, INC. (US)
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]